DOUGLAS RICHARD — SEC insider filings

SEC reporting owner CIK 1021015. 28 insider filings on record with FilingPulse; latest filed 2026-11-13.

Transaction summary — filings shown

Covers all 28 filings on record, filed 2021-01-05 to 2026-11-13. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.

By issuer — same filings

Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.

IssuerRole (as filed)FilingsPurchases (P)Sales (S)Other legs
MAXCYTE, INC. (MXCT)Director93 legs · 180,000 sh · $678,920—9
Aldeyra Therapeutics, Inc. (ALDX)Director82 legs · 270,000 sh · $226,900—18
NOVAVAX INC (NVAX)Director11——28

Insider filings — DOUGLAS RICHARD

FiledFormIssuerReported transactionsSource
2026-11-134Aldeyra Therapeutics, Inc. (ALDX)Purchase (P): 200,000 @ $0.64EDGAR
2026-06-234NOVAVAX INC (NVAX)Option exercise (M): 18,880 · Grant/award (A): 21,270 (derivative) @ $0 · Grant/award (A): 14,180 (derivative) @ $0 · Option exercise (M): 18,880 (derivative) @ $0EDGAR
2026-06-224MAXCYTE, INC. (MXCT)Grant/award (A): 30,421 @ $0 · Grant/award (A): 49,579 (derivative) @ $0EDGAR
2026-06-114Aldeyra Therapeutics, Inc. (ALDX)Grant/award (A): 70,000 (derivative) @ $0 · Grant/award (A): 19,909 (derivative) @ $0 · Grant/award (A): 2,323 (derivative) @ $0EDGAR
2026-03-204Aldeyra Therapeutics, Inc. (ALDX)Purchase (P): 70,000 @ $1.40EDGAR
2025-08-134MAXCYTE, INC. (MXCT)Purchase (P): 80,000 @ $1.39EDGAR
2025-06-244NOVAVAX INC (NVAX)Grant/award (A): 28,326 (derivative) @ $6.42 · Grant/award (A): 18,884 (derivative) @ $0EDGAR
2025-06-234MAXCYTE, INC. (MXCT)Grant/award (A): 29,210 @ $0 · Grant/award (A): 50,790 (derivative) @ $0EDGAR
2025-06-134NOVAVAX INC (NVAX)Option exercise (M): 10,420 @ $0 · Option exercise (M): 10,420 (derivative) @ $0EDGAR
2025-06-124Aldeyra Therapeutics, Inc. (ALDX)Grant/award (A): 62,728 (derivative) @ $0 · Grant/award (A): 14,476 (derivative) @ $0 · Grant/award (A): 1,689 (derivative) @ $0EDGAR
2024-06-144NOVAVAX INC (NVAX)Option exercise (M): 6,670 @ $0 · Option exercise (M): 6,670 (derivative) @ $0 · Grant/award (A): 15,630 (derivative) @ $15.86 · Grant/award (A): 10,420 (derivative) @ $0EDGAR
2024-06-134MAXCYTE, INC. (MXCT)Grant/award (A): 21,367 @ $0 · Grant/award (A): 40,701 (derivative) @ $0EDGAR
2024-06-064Aldeyra Therapeutics, Inc. (ALDX)Grant/award (A): 40,282 (derivative) @ $0 · Grant/award (A): 10,418 (derivative) @ $0 · Grant/award (A): 1,215 (derivative) @ $0EDGAR
2023-07-054Aldeyra Therapeutics, Inc. (ALDX)Grant/award (A): 21,222 (derivative) @ $0 · Grant/award (A): 5,488 (derivative) @ $0 · Grant/award (A): 640 (derivative) @ $0EDGAR
2023-06-234MAXCYTE, INC. (MXCT)Grant/award (A): 50,000 (derivative) @ $0EDGAR
2023-06-134NOVAVAX INC (NVAX)Option exercise (M): 3,100 · Option exercise (M): 3,100 (derivative) @ $0 · Grant/award (A): 7,710 (derivative) @ $0 · Grant/award (A): 6,670 (derivative) @ $0EDGAR
2023-03-304MAXCYTE, INC. (MXCT)Purchase (P): 80,000 @ $4.32EDGAR
2022-07-084MAXCYTE, INC. (MXCT)Grant/award (A): 26,900 (derivative) @ $0EDGAR
2022-06-214NOVAVAX INC (NVAX)Option exercise (M): 700 · Option exercise (M): 700 (derivative) @ $0EDGAR
2022-06-144NOVAVAX INC (NVAX)Grant/award (A): 4,600 (derivative) @ $0 · Grant/award (A): 3,100 (derivative) @ $0EDGAR
2022-06-094Aldeyra Therapeutics, Inc. (ALDX)Grant/award (A): 53,812 (derivative) @ $0 · Grant/award (A): 13,917 (derivative) @ $0 · Grant/award (A): 1,624 (derivative) @ $0EDGAR
2021-12-154NOVAVAX INC (NVAX)Option exercise (M): 1,500 @ $25.60 · Option exercise (M): 1,500 (derivative) @ $0EDGAR
2021-11-234MAXCYTE, INC. (MXCT)Purchase (P): 20,000 @ $11.12EDGAR
2021-08-114MAXCYTE, INC. (MXCT)Grant/award (A): 10,000 (derivative) @ $0EDGAR
2021-06-294NOVAVAX INC (NVAX)Option exercise (M): 3,450 · Option exercise (M): 3,450 (derivative) @ $0EDGAR
2021-06-224NOVAVAX INC (NVAX)Grant/award (A): 1,300 (derivative) @ $0 · Grant/award (A): 700 (derivative) @ $0EDGAR
2021-06-104Aldeyra Therapeutics, Inc. (ALDX)Grant/award (A): 13,534 (derivative) @ $0 · Grant/award (A): 3,500 (derivative) @ $0 · Grant/award (A): 408 (derivative) @ $0EDGAR
2021-01-054NOVAVAX INC (NVAX)Option exercise (M): 1,000 @ $50 · Option exercise (M): 1,000 (derivative) @ $0EDGAR

FilingPulse's Form 4 archive currently extends back to 2020-10-29 and is expanding backward through EDGAR history; Forms 3 and 5 are covered live-forward since 2026-09-23 (no 3/5 history). Earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.

Need this as JSON? GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1021015 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. Get a free API key → · API docs